HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate
methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate · 1,4-Dioxaspiro[4.5]decane-8-carboxylic Acid Methyl Ester
![Molekülstruktur von Methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate](/img/chemical/10845708.png)
Identifikatoren & physikalische Daten
| CAS No. | 26845-47-6 |
|---|---|
| Summenformel | C10H16O4 |
| Durchschnittliche Molmasse | 200,23 g/mol |
| Monoisotopische Masse | 200,10485899 g/mol |
| SMILES | COC(=O)C1CCC2(CC1)OCCO2 |
| InChIKey | XUTIURCKMWHHLX-UHFFFAOYSA-N |
| PubChem CID | 10845708 |
| EC No. | 869-783-1 |
| DTXSID | DTXSID00445699 |
Chemische & physikalische Eigenschaften
| XLogP | 0,7 |
|---|---|
| Polarare Oberfläche (TPSA) | 44,8 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 2 |
| Schwere Atome | 14 |
| Formalladung | 0 |
| Komplexität | 210 |
| Siedepunkt | 96-100 °C |
| Dichte | 1.15±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Inert atmosphere,Room Temperature |
| Aggregatzustand | clear liquid |
| Farbe | Colorless to Almost colorless |
| CAS Datenbank | 26845-47-6 |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%)Eye Irrit. 2A (100%)STOT SE 3 (100%) |
| Zollcode | 2932.99.9090 |
Anwendungen & Verwendung
Verwenden
methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate is a reagnet used in the preparation of pharmaceutical compounds such as high affinity H3 receptor agonists and reverse hydroxamate-based selective TACE inhibitors.